Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Geron and Sienna Cancer Diagnostics have signed a license agreement allowing Sienna access to critical granted patents and know-how related to the detection or measurement of telomerase activity.
Subscribe to our email newsletter
Under the terms of the license, Sienna gains worldwide exclusive rights within a defined field to Geron-controlled intellectual property to detect telomerase activity for the cancer in vitro diagnostics market. In consideration for the license, Geron received a significant equity interest in Sienna and is entitled to receive royalties on future product sales.
Kerry Hegarty, CEO of Sienna, said: “Sienna’s pathway to commercialization is now well-defined, secured by the agreement with Geron and a solid and talented workforce.”